Evasc Neurovascular Announces European Distributors

VANCOUVER, CANADA – January 4, 2018 – Evasc Neurovascular Enterprises ULC announced today that it has signed distribution agreements with five European distributors:

  • ab medica Deutschland GmbH & Co. (Germany)
  • Angiocare BV (Netherlands)
  • CardiRad AS (Nordic: Norway, Sweden, Denmark & Finland)
  • Plus Medica GmbH (Austria)
  • 1A Medical AG (Switzerland)

“Establishing a strong European sales channel is the next step in our growth strategy and we look forward to working with our new Distributors. These new partners are leaders in the neurovascular field and will be the foundation of our Distributor network in Europe.” said Dr. Donald Ricci, President and Chief Executive Officer of Evasc.

Jørn Erik Jacobsen, Chief Executive Officer of CardiRad AS, stated “We are very pleased to work with Evasc and bring its cutting edge eCLIPS device to the Nordic market. eCLIPS can be a key device in the treatment of cerebral aneurysms at bifurcations, and result in improved positive patient outcomes.’

Dr. Georg Landsberg, CEO of ab medica Deutschland, added “Given the efficacy advantages of eCLIPS, as supported by positive initial clinical data, we believe eCLIPs will rapidly find success in the German market."

About the eCLIPs Aneurysm Treatment System

In development since 2008, eCLIPs is a patented endovascular device designed to treat 95% of cerebral aneurysm cases, and is currently targeted for use in challenging wide-neck bifurcations. eCLIPs combines the best properties of stents and diverters, and can be used for coil retention and to enhance flow disruption. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac, while protecting and providing a platform for endothelial growth across the bifurcation neck.  To date, eCLIPs has been used to treat cerebral aneurysms in over 40 patients in Canada and 8 European countries.

About Evasc Neurovascular

Evasc Neurovascular is a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc received approval for use of eCLIPs in Canada under the Special Access Program in 2013, and received CE mark approval in 2015. Evasc is headquartered in Vancouver, Canada.

Evasc Neurovascular is on the web at www.evasc.com.

For more information, contact Scott Wilson at +1 (604) 742-3811, wilson@evasc.com.